The National Association of Chain Drug Stores on Wednesday announced that the Orlando Sentinel published a letter to the editor from NACDS president and CEO Steve Anderson that outlines the way pharmacists approach complex prescription pain medication issues.
Pain is proving to be a significant factor when it comes to sleeping patterns of Americans, according to a new poll by the National Sleep Foundation. Those suffering with chronic pain reported an average 42 minute sleep debt, whereas Americans who have experienced acute pain within the past week report a deficit of 14 minutes.
Emphasizing the importance of promoting policies that improve patient outcomes and lead to healthier, safer communities, the National Association of Chain Drug Stores submitted a statement to the U.S. House Committee on Energy and Commerce Subcommittee on Health in lead-up to Tuesday’s hearing titled, “Examining Public Health Legislation to Help Patients and Local Communities.”
More than 1-in-10 patients within the National Cardiovascular Disease Registry’s Practice Innovation and Clinical Excellence registry were receiving inappropriate aspirin therapy for primary prevention of cardiovascular disease.
Australian Dream is one of those hot external analgesic products that has been growing by greater than 20% across all channels. Drug Store News had an opportunity to dig a little deeper regarding the Nature s Health Connection s Australian Dream product with David Biernbaum of David Biernbaum and Assoc., who represents the product.
External analgesics is a category replete with growth brands with a base of $497.8 million across total U.S. multi-outlets, and more than 8.1% in growth for the 52 weeks ended Sept. 7, according to IRI data.
From 2009 to 2013, the number of Americans using prescription opiates declined 9.2%, yet both the number of opioid prescriptions filled and the number of days of medication per prescription rose more than 8% in that time period.
The pros of giving healthy women regular low dose aspirin to stave off such serious illness as cancer and heart disease are outweighed by the cons, suggests a large study published online last week in the journal Heart.
Purdue Pharma on Thursday announced that the Food and Drug Administration approved Hysingla ER (hydrocodone bitartrate) extended‐release tablets CII, a once‐daily, single‐entity medication formulated using Purdue’s proprietary extended‐release solid oral platform, Resistec.